BioRestorative TherapiesSTU:9OF -1.25%60 PB Ratio is 3.07 as of Jul. 01, 2026, which is 190% above its 10-year median of 1.06. GuruFocus rates STU:9OF with a GF Score™ of 60/100 and a GF Value™ of €1.27 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, BioRestorative Therapies ranks worse than 54.27% on this metric.
The historical rank and industry rank for BioRestorative Therapies's PB Ratio or its related term are showing as below:
STU:9OF'
s PB Ratio Range Over the Past 10 Years
Min: 0.52 Med: 1.06 Max: 31.28
Current: 3.18
During the past 13 years, BioRestorative Therapies's highest PB Ratio was 31.28. The lowest was 0.52. And the median was 1.06.
STU:9OF's PB Ratio is ranked worse than 54.27% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs STU:9OF: 3.18
During the past 12 months, BioRestorative Therapies's average Book Value Per Share Growth Rate was -85.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -75.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioRestorative Therapies was 91.80% per year. The lowest was -75.90% per year. And the median was 9.70% per year.
Back to Basics: PB Ratio
BioRestorative Therapies (STU:9OF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioRestorative Therapies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioRestorative Therapies (STU:9OF) has a PB Ratio of 3.07 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioRestorative Therapies and its competitors. This is 190% above median its historical median of 1.06. Over the past decade, BioRestorative Therapies' PB Ratio has ranged from 0.52 to 31.28. According to the industry distribution chart, BioRestorative Therapies ranks #667 out of 1229 companies in the Biotechnology industry, placing it in the top 54.3%.
Is BioRestorative Therapies' PB Ratio too high?
BioRestorative Therapies' current PB Ratio of 3.07 is 190% above median its 10-year median of 1.06. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 31.28. The Biotechnology industry median PB Ratio is 2.87. BioRestorative Therapies' value of 3.07 is 7% above this industry median. Based on the distribution chart, BioRestorative Therapies ranks #667 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioRestorative Therapies has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' PB Ratio compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #667 out of 1229 companies for PB Ratio. This places BioRestorative Therapies in the lower half of its industry. The industry median PB Ratio is 2.87. BioRestorative Therapies' value of 3.07 is 7% above this benchmark. Historically, BioRestorative Therapies' own PB Ratio has ranged from 0.52 to 31.28 over the past decade. While the company's 10-year median is 1.06 vs. the industry median of 2.87, BioRestorative Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current PB Ratio of 3.07 is 7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current PB Ratio is 3.07, which is 190% above median its own 10-year median of 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (STU:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.27, compared to a current price of €0.32 — trading 75.1% below its estimated fair value. The current PB Ratio is 3.07, which is 190% above median its 10-year median of 1.06 and 7% above the Biotechnology industry median of 2.87. BioRestorative Therapies' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioRestorative Therapies (STU:9OF), the current PB Ratio is 3.07 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (STU:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.32 is trading 75.1% below its estimated GF Value™ of €1.27.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for STU:9OF:
PB Ratio: 3.07 (190% above median its 10-year median of 1.06)
GF Value™: €1.27 vs. price of €0.32 (75.1% below fair value)
Industry Position: 7% above the Biotechnology median (#667 of 1229)
No single metric tells the full story. See the STU:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
60GF Score
Get the complete analysis for STU:9OF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9OF has been successfully added to your 
